MICROPORE Technologies has announced a licence agreement for its membrane technology with South Korean company G2GBIO.
G2GBIO will use Micropore’s membrane technology its for sustained-release pharmaceutical products. G2GBIO manufactures long-acting drugs for the treatment of conditions such as dementia, schizophrenia, cancer, and diabetes. It already has technology to manufacture monodisperse microspheres and Micropore’s high-throughput membrane encapsulation technology will help G2GBIO to scale up production. It will be able to manufacture 1 kg/h of emulsion with uniformly-sized particles, which equates to 1,000 vials of drugs for the treatment of Alzheimer’s disease.
Dai Hayward, CEO of Micropore, said: “We are delighted with yet another symbiotic collaboration with a global partner to demonstrate the inherent advantages of our technology in GMP applications. Our capability of delivering near-monodispersity in encapsulated particles cost-efficiently at commercially realistic volumes will help G2GBIO to capitalise on their innovative formulations.”
Heeyong Lee, CEO of G2GBIO, said: “We are pleased to collaborate with Micropore to develop various monodisperse microsphere drugs efficiently. We believe that our close relationship with Micropore has increased the likelihood of successful clinical and commercial production of a variety of microsphere drugs under development, including our innovative one-month long acting Alzheimer’s drug.”
Catch up on the latest news, views and jobs from The Chemical Engineer. Below are the four latest issues. View a wider selection of the archive from within the Magazine section of this site.